Boehringer Ingelheim, headquartered in Ingelheim, Germany, is a global, privately-held, research-driven pharmaceutical corporation that creates value through innovation for human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. Boehringer Ingelheim is now one of the world’s top 20 pharmaceutical companies.

Since its establishment in 1885, in-house research and development (R&D) has been the foundation of Boehringer Ingelheim’s success and continues to be the major driver of innovative new medicines that help improve patients’ lives and address unmet therapeutic needs. Our privately-held status enables us to act with long-term responsibility and in a value-based manner to meet the unique challenges and long cycles of drug discovery and development. The key therapeutic areas where Boehringer Ingelheim’s R&D seeks innovation include respiratory diseases, immunology, oncology, cardiovascular-metabolic diseases, and diseases of the central nervous system.

The Nonclinical Drug Safety department located in Ridgefield, CT, U.S.A., will be leading Boehringer Ingelheim’s contributions to the TransQST project.